TORCH-LATAM: A Regional Pathway to Improve Transplant Evaluation for Congenital Heart Disease
- Sponsor
- CardioVision International Tech, S.A.S. de C.V.
- Study ID
- NCT07799272
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Congenital Heart Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 0 Days - N/A
- Healthy Volunteers
- Not accepted
Interventions
- TORCH Integrated Transplant Access Pathway (TORCH-ITAP) — OTHERTORCH-ITAP is a multicomponent regional health-services pathway that standardizes early identification and referral, a common recipient dataset, multidisciplinary candidacy adjudication, structured donor-organ assessment, immunologic and anatomic-physiologic matching, preservation and transport traceability, and navigation of clinical, regulatory, logistical, and financial barriers. It supports authorized transplant pathways but does not allocate organs or supersede applicable law, competent authorities, or institutional authorization.
Study Details
Congenital heart disease can progress to advanced cardiac or cardiopulmonary failure requiring heart, heart-lung, or, in selected congenital conditions, bilateral lung transplantation with cardiac repair. Access to transplant evaluation and organ utilization can vary across regions and institutions, and potential candidates who are never referred or evaluated are not represented in conventional waiting-list statistics. TORCH-LATAM is a pragmatic multicenter stepped-wedge cluster-randomized effectiveness-implementation trial evaluating the TORCH Integrated Transplant Access Pathway (TORCH-ITAP) in Latin America. Regional network clusters transition in a randomized sequence from usual care to TORCH-ITAP. The pathway standardizes early identification and referral, a common recipient dataset, multidisciplinary candidacy adjudication, structured donor-organ assessment, immunologic and anatomic-physiologic matching, preservation and transport traceability, and navigation of clinical, regulatory, logistical, and financial barriers. The primary outcome is the proportion of enrolled recipient participants who complete a standardized multidisciplinary transplant evaluation and receive a documented candidacy decision within 90 days. Secondary outcomes include activation of an official transplant pathway or waitlist where applicable, transplantation within 12 months, pretransplant death or irreversible deterioration, donor-organ utilization, post-transplant safety and survival, and implementation outcomes. Recipient participants constitute the ClinicalTrials.gov enrollment; donors, organs, donor-recipient matches, preservation strategies, and transplant episodes are nested analytic units. TORCH-ITAP does not allocate organs and does not supersede national transplant laws, authorized transplant programs, or governmental requirements for cross-border organ movement.
Key Dates
- First listed
- Sep 2, 2026
- Start date
- Mar 31, 2027
- Status verified
- Aug 2026
- Primary completion
- Sep 30, 2029
- Completion
- Jun 30, 2031
Study Design
- Enrollment
- 600 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- No Intervention: Usual Care PhaseParticipants receive the site-specific usual transplant referral and evaluation pathway. Minimum study measurement is collected without activation of TORCH-ITAP.
- Experimental: TORCH-ITAP PhaseThe regional network implements TORCH-ITAP, including standardized identification and referral, common-data assessment, candidacy adjudication, donor-organ and match workflow, and structured navigation and traceability.
Primary Outcome Measure
Percentage of Participants Completing Standardized Multidisciplinary Transplant Evaluation With a Documented Candidacy Decision [ Time Frame: Within 90 days after formal trial enrollment ]
Central Contacts
- Eliecer Villamizar De La Hoz, MD50370876226
Related Studies
- Molecular and Cellular Characterization of Cardiac Tissue in Postnatal DevelopmentRecruiting · Emory University · Atlanta, Georgia
- Genetics of Congenital Heart DiseaseRecruiting · Nationwide Children's Hospital · Columbus, Ohio
- MRI and Computational Simulation Cardiology StudyEnrolling By Invitation · Stanford University · Palo Alto, California
- ATrial Tachycardia PAcing Therapy in Congenital HeartRecruiting · Ian Law · Los Angeles, California